Branded Legacy, Inc. Reports Significant Net Income of Over $3.8 Million

Apr 15, 2024 | Brands, Company Investment, Manufacturing and Processing, News, Partnerships and Collaborations

Royal Biotek Enhances Everglade Line with New Products

Melbourne, FL – April 16, 2024 – Branded Legacy, Inc. (OTC.PK: BLEG), a leading provider of innovative wellness products, is pleased to announce a net income for the fiscal year 2023 of $3,825,527, a substantial increase driven by the strategic retirement of over 2.4 billion shares. As they forge into 2024, the company has signed multiple on-going white label contracts, poised to further enhance our revenue and profitability for the coming year and beyond.

“2023 was a year of substantial growth and strategic repositioning for Branded Legacy. As we continue to expand and innovate, our focus remains steadfast on leveraging our core strengths in biotechnology to improve human health globally,” said David Oswald, CEO of Branded Legacy.

In a remarkable development, Branded Legacy has welcomed Dr. Mark T. Hamann, the Endowed Chair of Drug Discovery and Biomedical Sciences at the MUSC College of Pharmacy, to guide its forthcoming clinical trials. This follows the Company’s recent strategic acquisition of Sycamore BioPharma, Inc., a distinguished developer of plant-based pharmaceuticals. This acquisition not only secured assets exceeding $2 million but also integrates key personnel vital for advancing their clinical trials.

The company’s recent strategic endeavors include the acquisition of several companies, bringing over $3.7 million worth of advanced scientific equipment and inventory. This expansion has necessitated a move to a larger, state-of-the-art facility in Melbourne, FL, to accommodate their growing operations and align with their commitment to biotechnological advancement and improving human health.

The Company’s total assets have seen an astronomical increase to $3,787,215.00, the majority in 2024, marking a 1,412% increase compared to the end of Q3. The newly acquired laboratory and packaging equipment significantly bolsters capacities in R&D, production, and packaging.

The extensive equipment range acquired includes High-Performance Liquid Chromatography and Gas Chromatography systems, various centrifuges, vacuum ovens, an irradiating flow hood, incubators, and more. This arsenal of advanced tools empowers the Company to conduct precise chemical analyses, foster controlled research environments, and enhance product development efficiency across various stages.

Furthering its expansion strategy, Branded Legacy, Inc. proudly announced its acquisition of MariJ Pharmaceuticals, Inc. This deal significantly broadens their asset base and intellectual property portfolio, integrating a compounding pharmacy license, state-of-the-art supercritical CO2 extraction units, and a fleet of specialized vehicles designed for mobile extraction and refinement.

This strategic acquisition delivers not only a suite of award-winning organic products and formulations but also enhances their operational flexibility and market reach through the addition of specialized vehicles and a mobile repair service. These assets are instrumental in maintaining the efficiency and reach of our operations across multiple states, including Colorado and Tennessee.

The acquisition of All In Extracts Llc. gave Branded Legacy a leg up in production of gummies, producing 20-50,000 units daily. The All In facility near Tampa, FL, has recently staged up production and refinement of mitragynine, as well as production of a proprietary dosing syrup. With several popular products under their Star Hill brand, All In Extracts is a core aspect of Branded Legacy’s growing revenue.

Branded Legacy, Inc. is poised to continue its trajectory of growth, innovation, and market leadership in the biotech and wellness industries.

 

Investor Relations & Media Contact:

Joe Holladay
Branded Legacy
Phone: 321-345-3565
Email: info@brandedlegacy.com

Download this Press Release

 

Safe Harbor Statement on Forward-Looking Language: This release includes forward-looking statements, which are based on certain assumptions and reflect management’s current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Dilution, if any, would be for the purposes of management taking stock in lieu of cash salary. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Additionally, this press release that is not statements of historical fact may be considered to be forward-looking statements. Written words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “intends,” “goal,” “objective,” “seek,” “attempt,” or variations of these or similar words, identify forward-looking statements. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future.